Alumis (NASDAQ:ALMS) Trading 6.6% Higher Following Insider Buying Activity

Alumis Inc. (NASDAQ:ALMS) traded up 6.6% during mid-day trading on Wednesday following insider buying activity. The stock traded as high as $23.94 and last traded at $23.5690. 1,274,140 shares were traded during trading, a decline of 89% from the average session volume of 11,453,423 shares. The stock had previously closed at $22.11.

Specifically, Director Srinivas Akkaraju bought 588,235 shares of the business’s stock in a transaction dated Friday, January 9th. The shares were acquired at an average price of $17.00 per share, with a total value of $9,999,995.00. Following the purchase, the director owned 1,853,488 shares in the company, valued at approximately $31,509,296. The trade was a 46.49% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Foresite Labs, Llc bought 411,764 shares of Alumis stock in a transaction that occurred on Thursday, January 8th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the acquisition, the insider directly owned 5,702,536 shares in the company, valued at approximately $96,943,112. This represents a 7.78% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In related news, Director James B. Tananbaum purchased 411,764 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $6,999,988.00. Following the acquisition, the director owned 5,702,536 shares in the company, valued at approximately $96,943,112. This trade represents a 7.78% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ALMS shares. Wells Fargo & Company upped their target price on Alumis from $17.00 to $39.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 6th. Leerink Partners boosted their price target on Alumis from $20.00 to $32.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 6th. Oppenheimer restated an “outperform” rating and issued a $50.00 price target on shares of Alumis in a report on Tuesday, January 6th. Wall Street Zen upgraded shares of Alumis from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 target price (up from $20.00) on shares of Alumis in a research note on Friday, January 9th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Alumis has a consensus rating of “Moderate Buy” and an average target price of $37.67.

Key Alumis News

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Director Srinivas Akkaraju purchased 588,235 shares at $17.00 (~$10.0M), increasing his stake by ~46% — a material insider buy that signals management confidence. Read More.
• Positive Sentiment: Director James B. Tananbaum (and affiliated Foresite entities) bought 411,764 shares at $17.00 (~$7.0M), lifting their holdings materially — institutional/insider demand typically boosts sentiment and liquidity. Read More.
• Positive Sentiment: Major shareholder Foresite Labs/Capital increased its position (411,764 shares at $17), reinforcing institutional support and amplifying the buying pressure. Read More.
• Positive Sentiment: Market headlines cite positive plaque‑psoriasis data for lead candidate Envudeucitinib — the clinical update is a direct fundamental catalyst behind the rapid run‑up in the stock. Read More.
• Positive Sentiment: An analyst price‑target lift was reported (79.14% increase to $36.28), reflecting the same bullish re‑rating driving buy‑side interest. Read More.
• Neutral Sentiment: Several firms have reissued “outperform/buy” ratings and higher targets (MarketBeat/coverage roundup); broader analyst coverage likely magnifies volatility but also improves liquidity. Read More.
• Neutral Sentiment: Institutional ownership changes (historic buys by multiple funds) mean the stock can see larger block trades and volume swings; that can support rallies but also increases headline sensitivity. Read More.
• Negative Sentiment: Fundamental risk remains: Alumis missed most recent quarterly EPS and revenue estimates and is loss‑making — clinical execution or disappointing future readouts could quickly reverse gains. Read More.

Alumis Stock Performance

The company’s fifty day simple moving average is $10.29 and its two-hundred day simple moving average is $6.34. The company has a market capitalization of $2.54 billion, a price-to-earnings ratio of -6.01 and a beta of -2.09.

Alumis (NASDAQ:ALMS) last issued its earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.14). The firm had revenue of $2.07 million for the quarter, compared to analyst estimates of $3.14 million. Sell-side analysts anticipate that Alumis Inc. will post -8.51 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its holdings in shares of Alumis by 320.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock valued at $26,000 after acquiring an additional 4,894 shares during the last quarter. Police & Firemen s Retirement System of New Jersey boosted its holdings in Alumis by 199.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 10,753 shares of the company’s stock worth $32,000 after purchasing an additional 7,165 shares during the period. New York State Common Retirement Fund increased its stake in Alumis by 173.7% during the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock valued at $35,000 after purchasing an additional 7,467 shares during the last quarter. Western Wealth Management LLC acquired a new stake in shares of Alumis during the second quarter worth $36,000. Finally, ProShare Advisors LLC bought a new position in shares of Alumis in the 2nd quarter worth about $40,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.